Petros Pharmaceuticals (PTPI) has received a staff determination letter from the Nasdaq Stock Market, informing the Company that Nasdaq determined to suspend trading and delist the Company’s common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros’ securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker “PTPI”.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTPI:
- Petros Pharmaceuticals partners with Innolitics
- Petros Pharmaceuticals strengthens partnership with big data provider
- AI Daily: Microsoft reports earnings, says Cloud, AI ‘essential inputs’
- Petros Pharmaceuticals developing SaaS Platform using AI, EHR
- Petros Pharmaceuticals trading halted, news pending